Evidence map›Paper›PMID 41142811›Full record

ArticleFrontiers in immunology2025

Case Report: Severe neutropenia induced by avelumab in a patient with Merkel cell carcinoma.

Eri Ohta, Kayo Yamamoto, Hitomi Fujimura, Natsuko Saito-Sasaki, Etsuko Okada, Yu Sawada

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eri OhtaDepartment of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kayo YamamotoDepartment of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hitomi FujimuraDepartment of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Natsuko Saito-SasakiDepartment of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Etsuko OkadaDepartment of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yu SawadaDepartment of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 78-year-old woman with a history of follicular lymphoma treated with obinutuzumab and bendamustine developed Merkel cell carcinoma (MCC) on her left forearm. After surgical excision, in-transit and lymph node metastases appeared within three weeks. Avelumab and radiotherapy were initiated, but severe neutropenia occurred after two doses, requiring G-CSF support and treatment discontinuation. Despite early cessation, metastatic lesions regressed. This case suggests that prior B-cell-directed therapy may increase the risk of hematologic toxicity with immune checkpoint inhibitors and that even short-term avelumab may induce a durable response in MCC.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Merkel CellNeutropeniaSkin NeoplasmsAgedFemaleHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalavelumabavelumabcase reportirAEMerkel cell carcinomaneutropenia

Identifiers

PMID41142811
PMCPMC12546029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.